Experienced in Choriocarcinoma

Dr. John V. Heymach

Oncology
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Choriocarcinoma
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Heymach is an Oncologist in Houston, Texas. Dr. Heymach is rated as an Experienced provider by MediFind in the treatment of Choriocarcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Tissue Biopsy.

His clinical research consists of co-authoring 497 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Choriocarcinoma.

Specialties
Oncology
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

MD Anderson
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR)
Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR)
Enrollment Status: Recruiting
Publish Date: May 13, 2025
Intervention Type: Other, Procedure, Radiation, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase II Study of Poziotinib in EGFR or HER2 Mutant Advanced Solid Tumors
A Phase II Study of Poziotinib in EGFR or HER2 Mutant Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Poziotinib
Study Phase: Phase 2
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
Enrollment Status: Completed
Publish Date: March 04, 2025
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Pilot Open-Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
A Pilot Open-Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: September 05, 2021
Intervention Type: Drug
Study Phase: Phase 1
BATTLE-FL: A Biomarker-Integrated Study in Patients With Advanced Non-Small Cell Lung Cancer Treated in the Front-Line (FL) Setting
BATTLE-FL: A Biomarker-Integrated Study in Patients With Advanced Non-Small Cell Lung Cancer Treated in the Front-Line (FL) Setting
Enrollment Status: Completed
Publish Date: May 15, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

497 Total Publications

The Next Layer: Augmenting Foundation Models with Structure-Preserving and Attention-Guided Learning for Local Patches to Global Context Awareness in Computational Pathology.
The Next Layer: Augmenting Foundation Models with Structure-Preserving and Attention-Guided Learning for Local Patches to Global Context Awareness in Computational Pathology.
Journal: ArXiv
Published: September 05, 2025
Similar Doctors
Distinguished in Choriocarcinoma
Dr. Matthew T. Campbell
Hematology | Oncology
Distinguished in Choriocarcinoma
Dr. Matthew T. Campbell
Hematology | Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.1 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Campbell is a Hematologist and an Oncologist in Houston, Texas. Dr. Campbell is rated as a Distinguished provider by MediFind in the treatment of Choriocarcinoma. His top areas of expertise are Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, and Nephrectomy.

Advanced in Choriocarcinoma
Dr. Martha P. Mims
Hematology Oncology | Hematology | Oncology
Advanced in Choriocarcinoma
Dr. Martha P. Mims
Hematology Oncology | Hematology | Oncology

Baylor College Of Medicine

6720 Bertner Ave, 
Houston, TX 
 (0.4 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Martha Mims is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Mims is rated as a Distinguished provider by MediFind in the treatment of Choriocarcinoma. Her top areas of expertise are Hypereosinophilic Syndrome, Essential Thrombocythemia, Non-Hodgkin Lymphoma, and Clear Cell Sarcoma. Dr. Mims is currently accepting new patients.

Advanced in Choriocarcinoma
Dr. Mohsen S. Arani
Hematology Oncology | Geriatrics | Hematology
Advanced in Choriocarcinoma
Dr. Mohsen S. Arani
Hematology Oncology | Geriatrics | Hematology

Texas Oncology PA

501 W Medical Ctr Blvd, 
Webster, TX 
 (20.4 miles away)
281-332-7505
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mohsen Arani is a Hematologist Oncology specialist and a Geriatrics provider in Webster, Texas. Dr. Arani is rated as a Distinguished provider by MediFind in the treatment of Choriocarcinoma. His top areas of expertise are Paget Disease of the Breast, Non-Hodgkin Lymphoma, Childhood Iron Deficiency Anemia, and Colorectal Cancer. Dr. Arani is currently accepting new patients in some locations.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Heymach's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile